Compare Incyte Corporation (INCY) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oscar Health Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Oscar Health Inc trades at $30.77 (market cap $8.92B). The key difference: Incyte Corporation is far larger — about 2.6× Oscar Health Inc's market cap. Which is the better fit depends on your goals.
| INCY | OSCR | |
|---|---|---|
Market Cap | $23.11B | $8.92B |
Sector | Health | Health |
52-Week High | $118.52 | $32.18 |
52-Week Low | $67.38 | $10.85 |
Enterprise Value | $19.13B | $4.55B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
